Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Chi Sheng Pharma & Biotech Co EV-to-EBITDA?
Chi Sheng Pharma & Biotech CoROCO:4111 -0.35%82 EV-to-EBITDA is 4.09 as of Sep. 09, 2026, which is 47% below its 10-year median of 7.76. GuruFocus rates ROCO:4111 with a GF Score™ of 82/100 and a GF Value™ of NT$33.19 (Modestly Undervalued). Among 516 Medical Devices & Instruments companies, Chi Sheng Pharma & Biotech Co ranks better than 90.7% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Chi Sheng Pharma & Biotech Co's enterprise value is NT$1,290 Mil.
Chi Sheng Pharma & Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$315 Mil. Therefore, Chi Sheng Pharma & Biotech Co's EV-to-EBITDA for today is 4.09.
The historical rank and industry rank for Chi Sheng Pharma & Biotech Co's EV-to-EBITDA or its related term are showing as below:
ROCO:4111'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.09 Med: 7.76 Max: 11.06
Current: 4.09
During the past 13 years, the highest EV-to-EBITDA of Chi Sheng Pharma & Biotech Co was 11.06. The lowest was 4.09. And the median was 7.76.
ROCO:4111's EV-to-EBITDA is ranked better than 90.7% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 13.965
vs ROCO:4111: 4.09
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Chi Sheng Pharma & Biotech Co (ROCO:4111) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Chi Sheng Pharma & Biotech Co's PE Ratio (TTM) for today is calculated as:
Chi Sheng Pharma & Biotech Co's share price for today is NT$28.70.
Chi Sheng Pharma & Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$3.130.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4111 vs ISRG, BDX, RMD: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Chi Sheng Pharma & Biotech Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chi Sheng Pharma & Biotech Co EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Chi Sheng Pharma & Biotech Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Chi Sheng Pharma & Biotech Co's EV-to-EBITDA falls into.
Chi Sheng Pharma & Biotech Co's current Enterprise Value is NT$1,290 Mil.
Chi Sheng Pharma & Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$315 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chi Sheng Pharma & Biotech Co (ROCO:4111) has a EV-to-EBITDA of 4.09 as of Sep. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Chi Sheng Pharma & Biotech Co. This is 47% below median its historical median of 7.76. Over the past decade, Chi Sheng Pharma & Biotech Co's EV-to-EBITDA has ranged from 4.09 to 11.06. According to the industry distribution chart, Chi Sheng Pharma & Biotech Co ranks #48 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 9.3%.
Is Chi Sheng Pharma & Biotech Co's EV-to-EBITDA too high?
Chi Sheng Pharma & Biotech Co's current EV-to-EBITDA of 4.09 is 47% below median its 10-year median of 7.76. Over the past 10 years, this metric has ranged from a low of 4.09 to a high of 11.06. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.97. Chi Sheng Pharma & Biotech Co's value of 4.09 is 70.7% below this industry median. Based on the distribution chart, Chi Sheng Pharma & Biotech Co ranks #48 out of 516 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Chi Sheng Pharma & Biotech Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chi Sheng Pharma & Biotech Co's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Chi Sheng Pharma & Biotech Co ranks #48 out of 516 companies for EV-to-EBITDA. This places Chi Sheng Pharma & Biotech Co in the top 9% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.97. Chi Sheng Pharma & Biotech Co's value of 4.09 is 70.7% below this benchmark. Historically, Chi Sheng Pharma & Biotech Co's own EV-to-EBITDA has ranged from 4.09 to 11.06 over the past decade. While the company's 10-year median is 7.76 vs. the industry median of 13.97, Chi Sheng Pharma & Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.97, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chi Sheng Pharma & Biotech Co's current EV-to-EBITDA of 4.09 is 70.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Chi Sheng Pharma & Biotech Co. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chi Sheng Pharma & Biotech Co's current EV-to-EBITDA is 4.09, which is 47% below median its own 10-year median of 7.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chi Sheng Pharma & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co (ROCO:4111) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$33.19, compared to a current price of NT$28.70 — trading 13.5% below its estimated fair value. The current EV-to-EBITDA is 4.09, which is 47% below median its 10-year median of 7.76 and 70.7% below the Medical Devices & Instruments industry median of 13.97. Chi Sheng Pharma & Biotech Co's overall GF Score™ is 82/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Chi Sheng Pharma & Biotech Co (ROCO:4111), the current EV-to-EBITDA is 4.09 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chi Sheng Pharma & Biotech Co (ROCO:4111) Overvalued in 2026?
Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co stock appears to be undervalued.
The current stock price of NT$28.70 is trading 13.5% below its estimated GF Value™ of NT$33.19.
GuruFocus considers Chi Sheng Pharma & Biotech Co to be Modestly Undervalued.
Key valuation signals for ROCO:4111:
EV-to-EBITDA: 4.09 (47% below median its 10-year median of 7.76)
GF Value™: NT$33.19 vs. price of NT$28.70 (13.5% below fair value)
Industry Position: 70.7% below the Medical Devices & Instruments median (#48 of 516)
No single metric tells the full story. See the ROCO:4111 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chi Sheng Pharma & Biotech Co Ltd manufactures and distributes medical medicines and equipment in Taiwan. It offers injections, including hemodialysis solutions, amino acid injections, vitamin injections, and externally applied medicines.
82GF Score
Get the complete analysis for ROCO:4111
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4111 has been successfully added to your 
